CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 26 filers reported holding CRISPR THERAPEUTICS AG in Q4 2016. The put-call ratio across all filers is - and the average weighting 2.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $12,705,000 | -35.6% | 444,708 | 0.0% | 3.49% | -2.8% |
| Q3 2018 | $19,723,000 | -24.5% | 444,708 | 0.0% | 3.59% | -43.1% |
| Q2 2018 | $26,131,000 | -4.0% | 444,708 | -25.3% | 6.31% | -57.1% |
| Q1 2018 | $27,227,000 | +128.4% | 595,642 | +17.3% | 14.70% | +163.7% |
| Q4 2017 | $11,922,000 | +26.4% | 507,730 | -3.8% | 5.58% | +27.4% |
| Q3 2017 | $9,431,000 | +11.6% | 527,730 | 0.0% | 4.38% | -26.3% |
| Q2 2017 | $8,454,000 | -33.8% | 527,730 | -10.0% | 5.94% | -9.2% |
| Q1 2017 | $12,767,000 | +7.4% | 586,475 | 0.0% | 6.54% | -23.1% |
| Q4 2016 | $11,882,000 | – | 586,475 | – | 8.51% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $32,581,000 | 55.55% |
| NEA Management Company, LLC | 1,590,002 | $103,907,000 | 5.19% |
| ARK Investment Management | 8,237,122 | $538,296,000 | 3.75% |
| Nikko Asset Management Americas, Inc. | 4,262,736 | $277,078,000 | 3.54% |
| CLOUGH CAPITAL PARTNERS L P | 414,767 | $27,105,000 | 2.89% |
| Integral Health Asset Management, LLC | 220,000 | $14,377,000 | 2.79% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,268,000 | 2.48% |
| HC Advisors, LLC | 53,944 | $3,525,000 | 2.43% |
| Green Alpha Advisors, LLC | 27,466 | $1,795,000 | 1.52% |
| EFG Asset Management (North America) Corp. | 84,356 | $5,516,000 | 1.28% |